These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


138 related items for PubMed ID: 21946392

  • 21. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.
    Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Hans-Henrik P.
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):118-21. PubMed ID: 21824990
    [Abstract] [Full Text] [Related]

  • 22. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M, Takeya Y, Tatara Y, Yamamoto K, Onishi M, Maekawa Y, Kamide K, Rakugi H.
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [Abstract] [Full Text] [Related]

  • 23. Current concepts: renin inhibition in the treatment of hypertension.
    Gradman AH, Pinto R, Kad R.
    Curr Opin Pharmacol; 2008 Apr; 8(2):120-6. PubMed ID: 18308634
    [Abstract] [Full Text] [Related]

  • 24. Aliskiren and losartan trial in non-diabetic chronic kidney disease.
    Woo KT, Choong HL, Wong KS, Tan HK, Foo M, Fook-Chong S, Lee EJ, Anantharaman V, Lee GS, Chan CM.
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):515-22. PubMed ID: 24742970
    [Abstract] [Full Text] [Related]

  • 25. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K, Weinberger MH, Constance CM, Ali MA, Jin J, Prescott MF, Keefe DL.
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [Abstract] [Full Text] [Related]

  • 26. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
    Hofstra JM, Deegens JK, Steenbergen EJ, Wetzels JF.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
    [Abstract] [Full Text] [Related]

  • 27. [The future of renin inhibition].
    Uresin AY, Baran E.
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [Abstract] [Full Text] [Related]

  • 28. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 29. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J.
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [Abstract] [Full Text] [Related]

  • 30. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 31. Effect of direct renin inhibitor monotherapy on proteinuria in overt diabetic nephropathy.
    Silaratana S, Sumransurp S, Duangchana S, Tasanarong A.
    J Med Assoc Thai; 2012 Jan; 95 Suppl 1():S18-23. PubMed ID: 23964439
    [Abstract] [Full Text] [Related]

  • 32. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
    Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Łysiak-Szydłowska W, Woźniak M, Rutkowski B.
    Acta Biochim Pol; 2010 Jan; 57(1):119-23. PubMed ID: 20309434
    [Abstract] [Full Text] [Related]

  • 33. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A, Salazar J.
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [Abstract] [Full Text] [Related]

  • 34. Aliskiren and dual therapy in type 2 diabetes mellitus.
    Ingelfinger JR.
    N Engl J Med; 2008 Jun 05; 358(23):2503-5. PubMed ID: 18525047
    [No Abstract] [Full Text] [Related]

  • 35. Renin inhibition in hypertension.
    Gradman AH, Kad R.
    J Am Coll Cardiol; 2008 Feb 05; 51(5):519-28. PubMed ID: 18237679
    [Abstract] [Full Text] [Related]

  • 36. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M, Ménard J, Bissery A, Guyene TT, Bura-Rivière A.
    Clin J Am Soc Nephrol; 2007 Sep 05; 2(5):947-55. PubMed ID: 17702736
    [Abstract] [Full Text] [Related]

  • 37. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y, Takaoka M, Iwata H, Tanaka K, Hirata Y, Nagai R, Sata M.
    Hypertens Res; 2012 Jan 05; 35(1):62-9. PubMed ID: 21833001
    [Abstract] [Full Text] [Related]

  • 38. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
    Lam S, Choy M.
    Cardiol Rev; 2007 Jan 05; 15(6):316-23. PubMed ID: 18090068
    [Abstract] [Full Text] [Related]

  • 39. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
    Agarwal R.
    Am J Physiol Renal Physiol; 2003 Apr 05; 284(4):F863-9. PubMed ID: 12505865
    [Abstract] [Full Text] [Related]

  • 40. Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients.
    López V, Martin M, Cobelo C, Aranda P, Cabello M, Sola E, Gutierrez C, Burgos D, Martínez D, Hernandez D.
    Transplant Proc; 2010 Oct 05; 42(8):2883-5. PubMed ID: 20970559
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 7.